PAREXEL Executive Honored With 2015 DIA Global Connector Award

BOSTON, June 15, 2015 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Alberto Grignolo, PhD, Corporate Vice President, PAREXEL Consulting, was awarded the DIA Global Connector Award.  DIA presented the award at the 2015 DIA Global Inspire Awards event during the 51^st Annual Drug Information Association (DIA) Meeting in Washington, D.C.  The honor recognizes Dr. Grignolo's meritorious service through a leadership role that has advanced the mission of DIA to foster innovation and to improve health and well-being worldwide. 

"We are proud that our colleague, Alberto Grignolo, received the 2015 DIA Global Connector Award.  Alberto has demonstrated his superior understanding of drug development and the unique way he can connect, navigate, and bring people together for a common cause," said Josef von Rickenbach, Chairman and CEO, PAREXEL International.

Dr. Grignolo is a global expert and frequent speaker on the topics of drug development, drug regulatory affairs, and the Japanese regulatory environment. He currently serves on the faculty of DIA's Regulatory Affairs training courses and as the Deputy Editor of DIA's member magazine, Global Forum. 

At PAREXEL, Dr. Grignolo developed the Company's Worldwide Regulatory Affairs and Drug Development Consulting Practice. Recently, he established PAREXEL's Japan Consulting Services during a two-year assignment in Tokyo. He is the Executive Sponsor of a number of global development programs and advises clients in the areas of drug development strategy, regulatory negotiation, and best regulatory and clinical practices. 

At the DIA 2015 Annual Meeting, Dr. Grignolo is chairing two sessions:

• Japan Regulatory Environment: Overview of the Organization, Processes, Systems, and Changes Affecting Pharmaceutical Development
• Emerging Practices in Product Commercialization Planning: How Cross Collaboration Is Redefining Product Development Planning

"As a member and volunteer with DIA for more than 30 years, Dr. Grignolo has demonstrated exceptional dedication to the organization and to advancing the mission through his many roles.  I can think of no one more deserving of the 2015 DIA Global Connector Award," said Barbara Lopez Kunz, Global Chief Executive, DIA.

About DIA's Inspire Awards

DIA's annual Inspire Awards are awarded to members who have a record of making a difference in the eco-system of health care product development and lifecycle management.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc. provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 80 locations in 51 countries around the world, and had approximately 17,440 employees in the third quarter.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.  All other trademarks are the property of their respective owners.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ materially from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisitions of ClinIntel Limited and Quantum Solutions India, or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 as filed with the Securities and Exchange Commission on May 1, 2015, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

Contacts:

Diana Martin, PAREXEL International 
Tel: +1 781-434-5516  
Email: [email protected]  

Cristi Barnett, PAREXEL International
Tel.: +1 781-434-4019
Email: [email protected]

Jenny Gardynski, PAN Communications 
Tel: +1 617-502-4300
Email: [email protected]

SOURCE PAREXEL International Corporation

Related Links

http://www.parexel.com